A Prospective Trial of 68Ga-PSMA and 18F-FDG PET/CT in Nonmetastatic Prostate Cancer Patients with an Early PSA Progression During Castration-Reference-Cited by-同舟云学术

A Prospective Trial of 68Ga-PSMA and 18F-FDG PET/CT in Nonmetastatic Prostate Cancer Patients with an Early PSA Progression During Castration

Published:2020-06-11 Issue:17 Volume:26 Page:4551-4558
ISSN:1078-0432
Container-title:Clinical Cancer Research
language:en
Short-container-title:Clin Cancer Res

Author:

Wang Beihe,Liu Chang,Wei Yu^ORCID,Meng Jin,Zhang Yingjian,Gan Hualei,Xu Xiaoping,Wan Fangning,Pan Jian,Ma Xuejun,Hu Silong,Freedland Stephen J.,Song Shaoli,Ye DingWei,Zhu Yao^ORCID

Funder

National Nature Science Foundation of China

Shanghai Rising-Star Program

Fudan University Shanghai Cancer Center Fund

Shanghai “Rising Stars of Medical Talent” Youth Development

Publisher

American Association for Cancer Research (AACR)

Subject

Cancer Research,Oncology

Cited by 51 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Interlesional response heterogeneity is associated with the prognosis of abiraterone treatment in metastatic castration-resistant prostate cancer;Med;2024-08

2. Initial [18F]DCFPyL PET/CT in treatment-naïve prostate cancer: correlation with post-ADT PSA outcomes and recurrence;European Journal of Nuclear Medicine and Molecular Imaging;2024-04-02

3. Impact of PSMA PET on Prostate Cancer Management;Current Treatment Options in Oncology;2024-01-25

4. Combination of [18F]FDG and [18F]PSMA-1007 PET/CT predicts tumour aggressiveness at staging and biochemical failure postoperatively in patients with prostate cancer;European Journal of Nuclear Medicine and Molecular Imaging;2024-01-11

5. PSMA PET for Detection of Recurrence;Seminars in Nuclear Medicine;2024-01